1. Home /
    2. Altai Protocol Library /
  2. New Protocol – Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol – Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas

New Protocol – Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas
Study:
  • Single-arm, multicentre, phase 2 trial
  • Had received at least one line of platinum-based chemotherapy
  • Advanced stage thymoma or thymic carcinoma
  • Avelumab 10 mg/kg/14 day and axitinib 5 mg x 2. (N:32)
Efficacy:
  • ORR: 34% (CR: 0, PR: 34%) and SD: 56%
  • mPFS: 7.5 months
  • DOR: 5.5 months
Safety:
  • Grade 1 or 2 infusion reactions: 9%
  • Grade ≥3 AEs: Hypertension:19%, CK increase:9%
  • Deaths due to adverse events: No

Lancet Oncol. 2022 Sep 9;S1470-2045(22)00542-3.

Conforti F, Zucali PA, Pala L, et al. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

https://doi.org/10.1016/s1470-2045(22)00542-3

Reviewed by Hasan Çağrı Yıldırım, MD on Sep 27, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More